The renin-angiotensin-aldosterone system (RAAS) plays a relevant role not only in the
pathophysiology of essential hypertension, but also in the development of hypertensive …

Recent randomized controlled trials showed that blockade of the renin–angiotensin system
(RAS) by angiotensin-converting enzyme (ACE) inhibitors and angiotensin II–receptor …

Introduction: The renin–angiotensin–aldosterone system (RAAS) is already the most
important target for drugs in the cardiovascular system. However, still new developments are …

The critical role played by the renin–angiotensin–aldosterone system (RAAS) in the
regulation of blood pressure and body fluid homeostasis has been well recognized …

The renin–angiotensin–aldosterone system (RAAS) plays a key role in the pathogenesis of
many disorders, including heart failure, coronary artery disease, hypertension, kidney …

Importance of the field: Arterial hypertension is highly prevalent in the general population. Its
contribution to the development and evolution of cardiovascular and renal disease is well …

The dysregulation of renin-angiotensin-system (RAS) plays a pivotal role in hypertension
and in the development of the related target organ damage (TOD). The main goal of treating …

Interruption of the renin-angiotensin-aldosterone system (RAAS) at different levels is target-
organ protective in several disease states; however, complete blockade is unlikely to be …

The prevalence of chronic kidney disease, currently estimated to vary between 8 and 12% in
the general population, is steadily rising due to aging and to the ongoing epidemic of …

Since the description in 1977 of the first angiotensin-converting enzyme (ACE) inhibitor,
captopril, by the Squibb group led by Ondetti and Cushman, ACE inhibitors have become …